| Document |
Document Title |
|
WO/2016/201203A1 |
Methods are disclosed for making 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-me
thylpiperazin-l-yl)methyl]-3-(trifluoromethyl)phenyl]benzami
de, intermediates and pharmaceutically acceptable salts thereof.
|
|
WO/2016/201319A1 |
The invention provides therapeutic, engineered protein/peptide compositions comprising e.g., RAGE antibodies, T-cell receptors to target a RAGE receptor (including soluble forms thereof) directly and/or via differential competition with ...
|
|
WO/2016/201368A1 |
The invention provides therapeutic, engineered protein/peptide compositions comprising e.g., RAGE antibodies, T-cell receptors to target a RAGE receptor (including soluble forms thereof) directly and/or via differential competition with ...
|
|
WO/2016/201238A1 |
Solid state forms of trisodium vaisartan : sacubitril, processes for their preparation, pharmaceutical compositions containing such solid state forms and treatment methods using the pharmaceutical compositions are described.
|
|
WO/2016/196751A1 |
Physiological cooling compounds of Structure 1, where R1 is p-menthyl or 2,3,4-trimethylpent-3-yl group and R2-R8 are hydrogen or alkyl groups. The combination of R2-R8 is such that the N-alkyl group is a branched C5 alkyl or branched or...
|
|
WO/2016/193740A1 |
The invention relates to a process for the preparation of one or more intermediate chemical compounds useful in the preparation of non-ionic contrast agents wherein the process is carried out continuously using one or more flow procedures.
|
|
WO/2016/197089A1 |
This disclosure describes pharmaceutical compositions and methods of use for N-acetylcysteine amide for the prevention and treatment of acetaminophen overdose.
|
|
WO/2016/190326A1 |
Provided are: a charge-transporting varnish that contains a charge-transporting substance comprising an oligoaniline derivative represented by formula (1), a charge-transporting substance that does not contain fluorine atoms, and an orga...
|
|
WO/2016/188835A1 |
The invention relates to branched soluble polymeric supports for membrane enhanced peptides synthesis (MEPS), and their use in MEPS.
|
|
WO/2016/184561A1 |
Novel inhibitors of the enzyme autotaxin are described. The inhibitors contain one or two zinc-binding groups at the appropriate distance, Also described are uses thereof, such as for the inhibition of autotaxin activity and the treatmen...
|
|
WO/2016/180275A1 |
Disclosed are AHU-377 intermediates and a method for preparing AHU-377 and AHU-377 intermediates. The above-mentioned method for preparing AHU-377 uses a chiral glycidyl benzyl ether as the starting raw material. Intermediate compound (3...
|
|
WO/2016/173818A1 |
A personal care composition comprising N-aralkylcarbonyldiamines. When such compounds are used in personal care compositions, they have been unexpectedly shown to enhance cell proliferation and epidermal thickness, traits associated with...
|
|
WO/2016/175272A1 |
The present invention provides a rubber composition obtained by kneading a compound represented by formula (I) (definitions of the groups in formula (I) are as shown in the description), a rubber ingredient, and a filler.
|
|
WO/2016/171538A1 |
The invention relates to a method for synthesising vanillylamides of organic acids, based on vanillin oxime, inorganic salts of vanillylamine or based on organic salts of vanillylamine having organic acids. The method involves: the chemi...
|
|
WO/2016/161996A1 |
The present invention provides a method of chiral resolution of racemic amines of the benzyl type by means of salts formed with tartaric acid of formula (3) and intermediate of formula (2), and their use in the synthesis of Apremilast of...
|
|
WO/2016/155566A1 |
The present invention provides a method for preparing a pregabalin intermediate, 3-carbamoymethyl-5-methylhexanoic acid, using a solvent-free reaction. The method comprises the following steps: a) cooling an ammonia water system to a cer...
|
|
WO/2016/159644A1 |
Disclosed are a novel benzoic acid amide derivative compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof or a solvate thereof. The novel compound and the like inhibit melamine gene...
|
|
WO/2016/156089A1 |
The present invention provides a cocrystal of agomelatine with pyruvic acid, methods of its preparation, and pharmaceutical compositions containing it.
|
|
WO/2016/159049A1 |
The present invention pertains to a compound that can be useful as an agent for the treatment and/or prevention of cancer, hepatitis, liver fibrosis, fatty liver, and the like.
|
|
WO/2016/151464A1 |
The present invention provides an improved process for the preparation of 8-chloro-1-phenyl- 1H-benzo[b][1,4]diazepine-2,4(3H,5H)-dione (hereafter referred to as the compound (IV)), which is useful as a key intermediate for the synthesis...
|
|
WO/2016/153011A1 |
The purpose of the present invention is to provide a cooling agent composition containing a novel methyl menthol derivative having no undesirable feeling of stimulation, malodor, bitterness, or the like, it being possible to use the cool...
|
|
WO/2016/150337A1 |
The present invention relates to a new crystal form of a compound of formula (I), a preparation method and a use thereof. The new crystal form provided in the present invention is stable and has a low hygroscopicity, and a purification p...
|
|
WO/2016/140045A1 |
The present invention relates to an amide-compound aqueous solution containing an amide compound and a surfactant. More specifically, the invention relates to an amide-compound aqueous solution that contains, per 1 kg of the amide compou...
|
|
WO/2016/135151A1 |
The present invention relates to the fields of organic electronics and photonics. More particularly, the present invention relates to fluorescent charge-transfer compounds emitting in the visible spectral range from blue to red, comprisi...
|
|
WO/2016/133733A1 |
The present invention provides methods for treating and/or preventing inflammatory diseases of the gastrointestinal tract with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, and the use of composit...
|
|
WO/2016/131371A1 |
Disclosed is a method for preparing a formamide compound, the method uses carbon dioxide, hydrogen and an amine compound as raw materials and a transition metal complex as a catalyst, and the reaction is carried out in an organic solvent...
|
|
WO/2016/130650A1 |
In one aspect, the invention relates to a compound of the structure: (1), or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention rel...
|
|
WO/2016/125163A1 |
The present disclosure concerns modified lipid compounds and their use in the formation of lipid assemblies. Specifically are disclosed lipid assemblies comprising (a) an amphoteric lipid comprising in covalent association with (i) one o...
|
|
WO/2016/123361A1 |
An alternative approach to formation of a C-C bond at a meta-position of an aromatic compound is disclosed that employs an ethylenically unsaturated bicyclic compound as a transient mediator to achieve meta-selective C-H activation with ...
|
|
WO/2016/119574A1 |
Discloses is a method for preparign one of components of a novel antihypertensive drug of LCZ696, i.e. sacubitril (sacubitril, AHU-377, I). The method comprises the following preparation steps: carrying out the steps of cyclization, addi...
|
|
WO/2016/121691A1 |
Provided is a resin which has a low linear thermal expansion coefficient and a low absorbance. This resin is characterized by comprising at least one structure that is selected from among structures represented by general formula (1) or ...
|
|
WO/2016/119017A1 |
The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer).
|
|
WO/2016/116797A1 |
The present invention relates to crystalline modification of (3,4- dichlorophenyl)propanamide (propanil), to a process for the preparation of the same, to pesticidal mixtures and compositions comprising the crystalline modification of 5 ...
|
|
WO/2016/115023A1 |
Radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of using the radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of manufacturing radiopaque monomers, polymers, and microspheres are...
|
|
WO/2016/102727A1 |
The invention relates to a group of compounds with a structural nucleus derived from phenylacetamide, having formula (I), which compounds can modulate the DREAM neuronal calcium sensor. Consequently, the invention also relates to the use...
|
|
WO/2016/101885A1 |
The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The ...
|
|
WO/2016/100156A1 |
The present invention is directed to heteroaryl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurologica...
|
|
WO/2016/096905A1 |
This invention concerns the first mild and efficient synthesis of primary amines and amides from aldehydes or ketones using a heterogeneous metal catalystand amine donor. The initial heterogeneous metal- catalyzed reaction between the ca...
|
|
WO/2016/100542A1 |
Disclosed are compounds, for example, compounds of formula (I), (Formula (I) wherein R, R0, R1-R8, n, X, Y, Y', and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a...
|
|
WO/2016/093175A1 |
According to the present invention, various tri(hetero)arylacetonitrile compounds are synthesized by reacting, in the presence of a palladium catalyst, a di(hetero)arylacetonitrile compound represented by the formula: CHAr1Ar2CN (Ar1 and...
|
|
WO/2016/092030A1 |
A sugar surfactant of formula (I), where R1 is H or an alkyl group comprising 1 to 3 carbon atoms and R2 is a polyhydroxy-hydrocarbyl group comprising a straight hydrocarbyl chain to which at least three hydroxyl groups are directly bond...
|
|
WO/2016/094117A1 |
Disclosed are compounds of Formula I, including all stereoisomers and salts thereof, wherein Q1, Q2 and R are as defined in the disclosure. Also disclosed is a method for preparing a compound of Formula I, comprising contacting a compoun...
|
|
WO/2016/088082A1 |
The present invention provides a compound of formula (I): (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents an...
|
|
WO/2016/086798A1 |
Disclosed are a crystalline free acid of a NEP inhibitor, a calcium salt polymorph of same, a preparation method for same, and applications thereof. The present invention relates to a crystalline free acid of the NEP inhibitor compound (...
|
|
WO/2016/079521A1 |
Compounds having therapeutic potential as androgen receptor modulators and anti- cancer agents, and methods of making such compounds, are provided. The compounds are structurally related to bicalutamide, enobosarm and enzalutamide, but b...
|
|
WO/2016/081769A1 |
In some aspects, the disclosure relates to self-ligating protein tags conjugated to a photocaging molecule and methods of their use.
|
|
WO/2016/080545A1 |
[Problem] To provide: a nanocomposite capable of easily and efficiently removing and simultaneously absorbing an oily component, a heavy metal, hydrogen sulfide, and an organic compound merely by adding wastewater, without requiring a pr...
|
|
WO/2016/079522A1 |
Compounds having therapeutic potential as androgen receptor modulators and anti- cancer agents, and methods of making such compounds, are provided. The compounds are structurally related to bicalutamide, enobosarm and enzalutamide, but b...
|
|
WO/2016/081440A1 |
Provided herein is a two-component photosensitizer, which demonstrated robust and selective killing effects for transfected HEK cells and affibody targeted A431 cancer cells when exposed to near infrared light excitation. Free MG2I is a ...
|
|
WO/2016/074651A1 |
An isolation and purification method of substances derived from AHU-377 of formula (1), characterized by conversion of the crude substance (1) to well-crystallizing salts with amines of formula (9) in the environment of a suitable organi...
|
